Italia markets closed

BioNTech SE (BNTX)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
163,73-19,38 (-10,58%)
Al 01:21PM EDT. Mercato aperto.

BioNTech SE

An der Goldgrube 12
Mainz 55131
Germany
49 6131 9084 0
https://www.biontech.de

Settore/iHealthcare
SettoreBiotechnology
Impiegati a tempo pieno3.082

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Prof. Ugur Sahin M.D.Co-Founder, CEO & Chair of the Management Board690,88kN/D1965
Dr. Ozlem Tureci M.D.Co-Founder, Chief Medical Officer & Member of Management Board684,77kN/D1967
Prof. Christoph Hubert Huber M.D., Ph.D.Co-Founder & Member of Supervisory Board60,03kN/D1944
Mr. Jens H. HolsteinCFO & Member of Management Board828,24kN/D1963
Dr. Sierk Poetting Ph.D.MD, COO & Member of Management Board725,47kN/D1973
Mr. Ryan RichardsonChief Strategy Officer, MD & Member of Management Board626,77kN/D1979
Mr. Sean MarettChief Bus. Officer, Chief Commercial Officer & Member of Management Board783,47kN/D1965
Sylke Maas Ph.D.VP of Investor Relations and Bus. StrategyN/DN/DN/D
Dr. James Timothy Patrick Ryan Ph.D.VP of Legal & Intellectual PropertyN/DN/DN/D
Michael BoehlerMD & Head of Global External CommunicationsN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2021 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Governance aziendale

L'ISS Governance QualityScore di BioNTech SE al 31 luglio 2022 è 5. I criteri di valutazione fondamentali sono revisione: 5; Consiglio di Amministrazione: 8; diritti degli azionisti: 1; retribuzione: 1.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.